Rheumatology   

Last SHINGRIX was about 4 years ago and both doses were given.

Does the presence of ILD change your approach?

For example, baseline QT prolongation, elderly age group, or underlying heart disease?

Are you aware of any data regarding relative risk of molluscum contagiosum infection in reference to DMARDs/biologics?

Are there any clinical trials underway to study additional therapies?

Would it be safe to resume and if so, when?

CDC Healthcare Guidance CDC Isolation and Work Restriction Guidance CDC Immunocompromised Guidance

How do you approach ongoing screening for TB in patients with history of treated latent TB, but have ongoing use of DMARDs and/or biologics given quan...

Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?

Additionally, is it correct to assume that IV therapies might be preferred vs oral treatment given alterations in GI absorption in PLE? 

Patient previously failed abatacept and Rituximab.

(Patient with active RA despite hydroxychloroquine)

Do you just use antibiotic prophylaxis if therapy is started prior to meningococcal vaccination?

Hepatitis screening labs revealing Hep B ag and core positivity with positive PCR

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

For example, healthcare workers who require these vaccines for employment

Do you stop methotrexate or adjust the dose?